Has Brian Chwiecko, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,148 in general payments to Brian Chwiecko, MD across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brian Chwiecko, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brian Chwiecko, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brian Chwiecko, MD

Pulmonary Disease · West Reading, PANPI 1457738700

Payments from drug & device makers

$4,148in general payments, 2019–2025

Across 101 payments — averaging $41.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intuitive Surgical$2K
GSK$758
Pulmonx Corporation$267
Insmed, Inc.$237
Boston Scientific$195
Bayer$132
plus $972 from 21 others

What the payments were for

Speaking & faculty fees$50012%
Travel & lodging$94223%
Food & beverage$2,68465%
Gifts$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intuitive Surgical	8	$1,586
GSK	26	$758
Pulmonx Corporation	2	$267
Insmed, Inc.	12	$237
Boston Scientific	2	$195
Bayer	2	$132
AstraZeneca(2 entities)	6	$98
Regeneron Healthcare Solutions, Inc.	4	$97
Merck	6	$95
Mylan Specialty L.p.	5	$89
Sanofi	4	$86
Verona Pharma, Inc.	3	$77
Boehringer Ingelheim	3	$66
United Therapeutics Corporation	2	$41
Amgen	2	$37
Mallinckrodt Hospital Products Inc.	1	$36
Harmony Biosciences LLC	1	$31
Actelion Pharmaceuticals US, Inc.	2	$31
Axsome Therapeutics, Inc.	2	$31
Grifols USA, LLC	1	$24
Baxter Healthcare	1	$21
Jazz Pharmaceuticals Inc.	1	$21
Avadel CNS Pharmaceuticals, LLC	1	$19
Ambu Inc.	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$19
ANI Pharmaceuticals, Inc.	1	$19
Teva Pharmaceuticals USA, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,148 in reported general payments places this provider in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$264,639

Medicare patients

792

Services billed

3,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	418	$367,308
Breo ElliptaFluticasone/Vilanterol	199	$100,871
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr	106	$72,685
FasenraBenralizumab	12	$69,479
Stiolto RespimatTiotropium Br/Olodaterol Hcl	36	$31,778
Spiriva RespimatTiotropium Bromide	40	$27,607
Fluticasone-SalmeterolFluticasone Propion/Salmeterol	67	$13,634
SymbicortBudesonide/Formoterol Fumarate	26	$11,993
Spiriva HandihalerTiotropium Bromide	12	$11,163
Incruse ElliptaUmeclidinium Bromide	23	$11,002
Arnuity ElliptaFluticasone Furoate	29	$10,195
Fluticasone-VilanterolFluticasone/Vilanterol	26	$8,582
Qvar RedihalerBeclomethasone Dipropionate	16	$8,241
Albuterol Sulfate HfaAlbuterol Sulfate	245	$7,456
Combivent RespimatIpratropium/Albuterol Sulfate	14	$6,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta	$758	$562,062775 claims
AstraZenecaFasenra, Symbicort	$98	$81,47338 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat	$66	$65,91090 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler	$14	$8,24116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 703 pulmonary disease providers in Pennsylvania.